Exchange: NASDAQ·Updated 07:53 PM EDT
News
all
press releases
$100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 22.44% on an annualized basis producing an average annual return of 33.55%. Currently, Cogent Biosciences has a market capitalizationread more...
Benzinga
More News
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks
If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 28.96% on an annualized basis producing an average annual return of 40.76%. Currently, Cogent Biosciences has a market capitalizationread more...
Benzinga
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now?
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now...
Yahoo! Finance: News
Lilly’s Phase 3 Breakthrough Ignites Race for the Next Cancer Stock Breakout
Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. $LLY, $NTHI, $COGT, $OLMA, $BMY, $PFE
24-7 Market News
RSI Alert: Cogent Biosciences (COGT) Now Oversold
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
Cogent Biosciences (NASDAQ:COGT) Releases Earnings Results
Cogent Biosciences (NASDAQ:COGT - Get Free Report) released its quarterly earnings data on Tuesday. The technology company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates...
MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have received an average rating of "Moderate Buy" from the fourteen analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine h...
MarketBeat
Teachers Retirement System of The State of Kentucky Invests $1.33 Million in Cogent Biosciences, Inc. $COGT
Teachers Retirement System of The State of Kentucky purchased a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 37,445 shares of the technology company's stock...
MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Drop in Short Interest
Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) was the recipient of a significant decline in short interest in April. As of April 15th, there was short interest totaling 12,038,491 shares...
MarketBeat

Advertisement|Remove ads.